Research led by the University of Copenhagen and Herlev-Gentofte University Hospital shows that individuals with the eating disorder anorexia nervosa have an abnormal gut microbiome that likely contributes to symptoms associated with the condition. Published in the April 17, 2023, issue of Nature Microbiology, the study showed multiple differences in the species and amounts of bacteria and viruses present in the gut of people with the condition compared with healthy controls.
Shijiazhuang Discovery Medicine Technology Co. Ltd. has divulged pranoprofen derivatives reported to be useful for the treatment of pain and eye disorders.
A study published online in the Proceedings of the National Academy of Sciences on April 14, 2023, showed that strokes cause numerous changes in gene activity in affected microvessels in the brain, and these changes were potentially targetable with existing or future drugs to alleviate brain injury or improve stroke recovery. Treatments available for stroke are very limited and are mainly focused on the recanalization of the obstructed larger cerebral arteries. However, it is known that strokes affect the cerebral microvasculature too, for which there are no current therapies in the clinic.
The loss of myelin in the cerebral cortex of multiple sclerosis (MS) patients could be recovered if oligodendrocytes, the cells that myelinate neuronal axons, work at a higher rate than they are destroyed. However, a group of scientists from the University of Munich have shown, in cortical MS mice, that this does not occur. The oligodendrocytes do not contribute to remyelination efficiently.
Xenon Pharmaceuticals Inc. has synthesized pyridinyl derivatives acting as sodium channel protein type 1 subunit α (SCN1A; Nav1.1) activators reported to be useful for the treatment of epilepsy.
Shin Nippon Biomedical Laboratories Ltd. (SNBL) agreed to acquire Satsuma Pharmaceuticals Inc.as part of a deal worth as much as $220 million that includes rights to the STS-101 migraine drug. Shin Nippon will pay 91 cents in cash per share, as well as a non-tradeable contingent value right worth up to $5.77 per share based on the potential sale, license, or other grant of rights of Satsuma’s migraine drug STS-101.
As expected, the serotonin-dopamine modulator Rexulti (brexpiprazole) from Otsuka Pharmaceutical Co. Ltd. and H. Lundbeck A/S for agitation in Alzheimer’s disease (AD) dementia, found favor April 14 at the joint meeting of the U.S. FDA’s Psychopharmacologic Drugs Advisory Committee (adcom) and the Peripheral and Central Nervous System Drugs Advisory Committee.
RSS
